Norges Bank
RNAC icon

Norges Bank’s Cartesian Therapeutics RNAC Stock Holding History

Norges Bank’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,433
Closed -$1.09M – 2155
2022
Q1 		$1.09M Buy
+29,433
New +$1.84M ﹤0.01% 2044
2021
Q4 		– Sell
-3,313
Closed -$414K – 2280
2021
Q3 		$414K Sell
3,313
-12,280
-79% -$1.48M ﹤0.01% 2220
2021
Q2 		$1.96M Buy
15,593
+7,520
+93% +$895K ﹤0.01% 2020
2021
Q1 		$1.1M Buy
+8,073
New +$1M ﹤0.01% 2042

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Norges Bank's RNAC Position: Q2 2022 in Review

Norges Bank sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 29,433 shares — an estimated $1.09M sold.

Norges Bank first reported a position in RNAC in Q1 2021 and held it in 4 quarters. The position peaked at $1.96M in Q2 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

  • Norges Bank reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Norges Bank sold 29,433 Cartesian Therapeutics shares in Q2 2022, an estimated $1.09M.
  • Norges Bank first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 4 quarters.
  • Norges Bank's Cartesian Therapeutics position peaked at $1.96M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.